As an emerging technology in precision medicine, the patient-derived organoid (PDO)
technology has been indicated to provide novel modalities to judge the sensitivity of …

Introduction: Most advanced colorectal cancers are aggressive, and there is a lack of
effective methods for selecting appropriate anticancer regimens. Patient-derived organoids …

Background Addition of oxaliplatin to adjuvant 5-FU has significantly improved the disease-
free survival and served as the first line adjuvant chemotherapy in advanced colorectal …

Gastrointestinal (GI) cancers (gastric cancer, oesophageal cancer, liver cancer, colorectal
cancer, etc.) are the most common cancers with the highest morbidity and mortality in the …

The conventional microwell-based platform for construction of organoid models exhibits
limitations in precision oncology applications because of low-speed growth and high …

An in vitro assay system using patient‑derived tumor models represents a promising
preclinical cancer model that replicates the disease better than traditional cell culture …

Patient-derived organoids (PDOs) have emerged as a promising platform for clinical and
translational studies. A strong correlation exists between clinical outcomes and the use of …

There is no effective method to predict chemotherapy response and postoperative prognosis
of colorectal cancer liver metastasis (CRLM) patients. Patient‐derived organoid (PDO) has …

Patient-derived tumor organoids (PDOs) currently represent important modeling tools in pre-
clinical investigation of malignancies. Organoid cultures conserve the genetic and …

Background Gastric cancer treatment is complicated by the molecular heterogeneity of
human tumor cells, which limits the efficacy of standard therapy and necessitates the need …